Literature DB >> 19359367

Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.

V A Mitchell1, H Kawahara, C W Vaughan.   

Abstract

Neurotensin modulates pain via its actions within descending analgesic pathways which include brain regions such as the midbrain periaqueductal grey (PAG). The aim of this study was to examine the cellular actions of neurotensin on PAG neurons. Whole cell patch clamp recordings were made from rat midbrain PAG slices in vitro to examine the postsynaptic effects of neurotensin and its effects on GABA(A) mediated inhibitory postsynaptic currents (IPSCs). Neurotensin (100-300 nM) produced an inward current in subpopulations of opioid sensitive and insensitive PAG neurons which did not reverse over membrane potentials between -50 and -130 mV. The neurotensin induced current was abolished by the NTS1 and NTS1/2 antagonists SR48692 (300 nM) and SR142948A (300 nM). Neurotensin also produced a reduction in the amplitude of evoked IPSCs, but had no effect on the rate and amplitude of TTX-resistant miniature IPSCs. The neurotensin induced inhibition of evoked IPSCs was reduced by the mGluR5 antagonist MPEP (5microM) and abolished by the cannabinoid CB(1) receptor antagonist AM251 (3 microM). These results suggest that neurotensin produces direct neuronal depolarisation via NTS1 receptors and inhibits GABAergic synaptic transmission within the PAG. The inhibition of synaptic transmission is mediated by neuronal excitation and action potential dependent release of glutamate, leading to mGluR5 mediated production of endocannabinoids which activate presynaptic CB(1) receptors. Thus, neurotensin has cellular actions within the PAG which are consistent with both algesic and analgesic activity, some of which are mediated via the endocannabinoid system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19359367      PMCID: PMC2714017          DOI: 10.1113/jphysiol.2008.167429

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  55 in total

1.  The effects of diphenhydramine and SR142948A on periaqueductal gray neurons and on the interactions between the medial preoptic nucleus and the periaqueductal gray.

Authors:  K D Kreitel; C B Swisher; M M Behbehani
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

2.  Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia.

Authors:  Anne Remaury; Natalio Vita; Sylvain Gendreau; Mireille Jung; Michelle Arnone; Martine Poncelet; Jean-Michel Culouscou; Gérard Le Fur; Philippe Soubrié; Daniel Caput; David Shire; Manfred Kopf; Pascual Ferrara
Journal:  Brain Res       Date:  2002-10-25       Impact factor: 3.252

3.  Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system.

Authors:  Philippe Sarret; Amélie Perron; Thomas Stroh; Alain Beaudet
Journal:  J Comp Neurol       Date:  2003-07-07       Impact factor: 3.215

4.  The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin.

Authors:  Douglas J Pettibone; J Fred Hess; Patricia J Hey; Marlene A Jacobson; Michael Leviten; Edward V Lis; Pierre J Mallorga; Danette M Pascarella; Melissa A Snyder; Jacinta B Williams; Zhizhen Zeng
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

5.  Identification of the receptor subtype involved in the analgesic effect of neurotensin.

Authors:  I Dubuc; P Sarret; C Labbé-Jullié; J M Botto; E Honoré; E Bourdel; J Martinez; J Costentin; J P Vincent; P Kitabgi; J Mazella
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

6.  Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro.

Authors:  C W Vaughan; M Connor; E E Bagley; M J Christie
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

7.  Neurotensin excitation of serotonergic neurons in the rat nucleus raphe magnus: ionic and molecular mechanisms.

Authors:  A H Li; T H Yeh; P P Tan; H M Hwang; H L Wang
Journal:  Neuropharmacology       Date:  2001-06       Impact factor: 5.250

8.  Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones.

Authors:  M Legault; P Congar; F J Michel; L-E Trudeau
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

9.  Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus.

Authors:  Kathryn G Commons; Rita J Valentino
Journal:  J Comp Neurol       Date:  2002-05-20       Impact factor: 3.215

10.  Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception.

Authors:  E Palazzo; I Marabese; V de Novellis; P Oliva; F Rossi; L Berrino; F Rossi; S Maione
Journal:  Neuropharmacology       Date:  2001-03       Impact factor: 5.250

View more
  12 in total

1.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

2.  Neurotensin speeds inhibition of dopamine neurons through temporal modulation of GABAA and GABAB receptor-mediated synaptic input.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

Review 3.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 4.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

5.  Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition.

Authors:  H-T Liao; H-J Lee; Y-C Ho; L-C Chiou
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray.

Authors:  Vanessa A Mitchell; Hyo-Jin Jeong; Geoffrey M Drew; Christopher W Vaughan
Journal:  Neuropsychopharmacology       Date:  2011-04-27       Impact factor: 7.853

7.  Targeting neurotensin as a potential novel approach for the treatment of autism.

Authors:  Ahmad Ghanizadeh
Journal:  J Neuroinflammation       Date:  2010-10-01       Impact factor: 8.322

8.  Endocannabinoids control vesicle release mode at midbrain periaqueductal grey inhibitory synapses.

Authors:  Karin R Aubrey; Geoffrey M Drew; Hyo-Jin Jeong; Benjamin K Lau; Christopher W Vaughan
Journal:  J Physiol       Date:  2016-09-15       Impact factor: 5.182

9.  CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain neurotensin.

Authors:  Parichehr Hassanzadeh; Fatemeh Rostami
Journal:  Iran J Basic Med Sci       Date:  2014-03       Impact factor: 2.699

10.  Neural Circuit in the Dorsal Raphe Nucleus Responsible for Cannabinoid-Mediated Increases in 5-HT Efflux in the Nucleus Accumbens of the Rat Brain.

Authors:  Rui Tao; Zhiyuan Ma
Journal:  ISRN Pharmacol       Date:  2012-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.